Cryonics Society Newsfeed

Function Health now lets members feed lab results into ChatGPT, Claude and Perplexity, turning AI answers into ones grounded in biology. Millions of people already type their symptoms into an AI chatbot before they type them into a search bar for a doctor’s office. It’s fast, free and available at 2 a.m. when the worry The post Function connects your lab results to the AI health chatbot you use appeared first on Longevity.Technology.

HCW Biologics received a Notice of Allowance from the U.S. Patent and Trademark Office for claims directed to the use of HCW9302 to treat alopecia areata. Together with four recently issued U.S. patents (Nos. 11,401,326; 11,987,619; 12,018,071; 12,516,112) covering compositions, nucleic acids encoding HCW9302, vectors and methods for treating autoimmune diseases, the company says its The post HCW Biologics wins key U.S. patent protection for hair loss drug appeared first on Longevity.Technology.

Scribe Therapeutics reported second-quarter 2026 financial results and pipeline progress. The company initiated a first-in-human phase 1 clinical trial of STX-1150 in Australia in mid-2026, according to the company, and presented late-breaking non-human primate data at the European Atherosclerosis Society showing up to 90% PCSK9 silencing and LDL-C reductions up to 68%, with a 0.75 The post Scribe Therapeutics starts first human trial for cholesterol-lowering gene therapy appeared first on Longevity.Technology.

Rapalogix Health has established a dedicated research laboratory at Princeton Innovation Center BioLabs in Princeton, New Jersey. According to the company, the facility expands the company’s internal research capabilities and will serve as the primary site for its translational research program into next-generation rapalogs, the proprietary compound class behind Re-Q Health, the company’s professional skincare The post Rapalogix Health opens Princeton laboratory to advance skin longevity research appeared first on Longevity.Technology.

China’s National Medical Products Administration approved the subcutaneous autoinjector formulation of LEQEMBI (lecanemab) as an initiation treatment for mild cognitive impairment due to alzheimer’s disease and mild alzheimer’s disease dementia. The approved regimen is 500 mg once weekly, administered as two consecutive 250 mg injections, and patients may switch between intravenous and subcutaneous administration during The post China approves Leqembi subcutaneous autoinjector for early Alzheimer’s appeared first on Longevity.Technology.

FibroBiologics, a Houston-based clinical-stage biotechnology company, announced that the United States Patent and Trademark Office issued U.S. Patent No. 12,721,866 on 1 September 2026, covering therapeutic use of fibroblasts in wound healing. The issued claims, the company says, include methods for topically administering compositions comprising 3D spheroid fibroblasts and fibroblast-derived materials such as extracellular vesicles, The post FibroBiologics granted US patent for fibroblast wound therapy appeared first on Longevity.Technology.

Mito Health has expanded its direct-to-consumer diagnostics marketplace into seven categories of preventive testing and, according to the company, has run more than one million lab tests. The company claims its catalog now includes more than 1,000 individual lab tests and panels, at-home test kits shipped nationwide, at-home blood draws in 35 states, imaging and The post Mito Health passes one million tests, expands preventive offerings appeared first on Longevity.Technology.

Insilico Medicine, a clinical-stage drug discovery company powered by generative artificial intelligence, will be included in the HKEX Tech 100 Index following methodology enhancements announced on 18 August 2026 that broaden exposure to emerging technology themes across the AI value chain. The changes will be implemented after the market close on 11 September 2026 and The post Insilico Medicine included in HKEX Tech 100 Index appeared first on Longevity.Technology.

Researchers here suggest that increased ERBB4 expression in neurons is an important driving mechanism in the onset and progression of Alzheimer's disease. One has to be cautious with such findings, even given the effort made by the researchers to show that human data is compatible with the hypothesis, because the mouse models of Alzheimer's disease in which these sorts of discovery are made are very artificial. Mice do not normal exhibit anything like Alzheimer's disease, so the models induce forms of dysfunction that result in something resembling Alzheimer's in humans. The model embodies assumptions about relevant mechanisms that may not be correct, and this is one of the reasons why progress towards therapies has been slow and painful. Single-nucleus RNA-sequencing analysis identified the emergence of

This is far from the only study to indicate that the children of long-lived individuals tend also to be long-lived. The open question is the degree to which this is genetic versus cultural transmission. The construction of very large population databases over the past few decades has produced evidence for genetics to play only a small role in life expectancy for the vast majority of people. Similarly the weight of evidence for lifestyle choice, particularly physical fitness, to be the presently dominant influence on life expectancy is compelling. Against that background, the hypothesis that centenarians are centenarians because they have favorable gene variants that might form the basis for age-slowing therapies faces an uphill battle. Centenarian lifespan extension is frequently accompanied by delayed onset of

Filmmaker Tim Maupin has spent a number of years developing The Last Generation to Die, a near-future film about what happens when the first true rejuvenation technologies arrive and who gets left behind. The project

Senescent cells accumulate with age in tissues throughout the body, disrupting tissue structure and function with inflammatory secretions. The growing burden of senescent cells is an important contributing cause of degenerative aging. A cell becomes senescent in response to damage induced by some form of stress, or more often when a somatic cell reaches the Hayflick limit on cellular replication. In youth senescent cells are efficiently cleared by the immune system, but immune system aging allows senescent cells to linger and grow in number. Immune cells themselves are prone to reaching the Hayflick limit and entering replicative senescence because they respond to a variety of issues with greater replication to multiply their efforts. Research into neurodegenerative conditions and the state of the aging brain has

Biotech posts $819.9m war chest and full slate of late-stage trial data as it races to become first FDA-approved oral drug for hair loss. Hair loss has always been treated like a cosmetic footnote in medicine, something to manage quietly rather than a condition worth serious drug development. Dermatologist-founded, late clinical-stage biopharmaceutical company Veradermics is The post Veradermics builds $820m war chest for oral hair loss pill appeared first on Longevity.Technology.

850 patients signed up for an Alzheimer’s trial needing 760. For a biotech betting everything on one pill, that’s the good kind of surprise. Trial enrollment is the part of drug development nobody writes headlines about. It’s slow, unglamorous and it’s also where a lot of promising drugs quietly die, not because the science failed, The post Annovis sails past enrollment goal on Alzheimer’s appeared first on Longevity.Technology.

LifespanningRx has launched the Peptide Explorer, an online educational tool designed to help users organize health goals and explore up to three peptide therapy candidates before clinical evaluation. The company says the experience takes about five minutes and uses a structured questionnaire covering areas such as energy and metabolism, body composition, recovery, healthy aging, cognitive The post LifespanningRx launches peptide explorer for clinician-guided reviews appeared first on Longevity.Technology.

Minicircle was named one of 10 finalists in the seven-year, $101 million XPRIZE Healthspan competition, placing the Austin, Texas gene therapy developer among contenders seeking measurable rejuvenation in adults aged 50 to 80. The competition drew about 1,400 teams from 58 countries; 600 entries were reviewed, and 40 teams previously received $250,000 to support early The post Minicircle named XPRIZE Healthspan finalist appeared first on Longevity.Technology.

According to United Therapeutics, the U.S. Food and Drug Administration has accepted a supplemental new drug application for nebulized Tyvaso (treprostinil) inhalation solution to treat idiopathic pulmonary fibrosis, and the company anticipates the agency’s review to be complete in late April 2027. The company claims that, if approved, nebulized Tyvaso would be the first and The post United Therapeutics seeks FDA approval for inhaled treatment for idiopathic pulmonary fibrosis appeared first on Longevity.Technology.

Long-lived bats are extreme outliers in the normal mammalian relationships between species body size, metabolic rate, and life span. They are small, have a high metabolic rate, and unlike near all other mammals with those characteristics, many bat species are long-lived. But bat species do exhibit a very wide range of life spans; near neighbor species can have very different paces of aging. Researchers here sequence the genomes of a number of different bat species in search of insight into the mechanisms driving longevity in bats. As is usually the case, the distant end goal of this sort of comparative biology of aging research is to find potential approaches to the development of longevity therapies. That is a long road, and little progress has been

Clonal hemotopoiesis is the emergence of patterns of potentially problematic mutations occurring in hematopoietic stem cells that then spread over time throughout the immune system, as these stem cells are the source of all immune cells. It is the most well studied form of the somatic mosaicism that occurs in all tissues, the spread of mutations originating in stem cell populations, with some correlational evidence for it to contribute to the development of other age-related conditions. Here researchers note that clonal hematopoiesis associates with idiopathic pulmonary fibrosis, an age related condition with causes that are poorly understood. The immune system is clearly important to health, but equally the research community is some way from fully understanding how exactly disruptive mutations cause downstream problems in tissues.

The most common metabolic diseases, such as type 2 diabetes or fatty liver disease leading to metabolic dysfunction-associated steatohepatitis (MASH), a fibrotic condition of the liver, are consequences of the dysfunctional state of metabolism that results from being overweight and sedentary. These conditions are rare in thin, fit people, even in later life when the damage of aging makes metabolism more vulnerable and inflammatory. Excess visceral fat tissue is known to promote the accumulation of senescent cells. While cells become senescent throughout life, in youth they are promptly cleared by the immune system. That clearance falters with age, allowing senescent cells to linger and accumulate. The metabolic dysfunction produced as a consequence of being overweight accelerates this process. In today's open access paper researchers review

Driven by ongoing support from their community, The Longevity Science Foundation is extending the deadline for the Invested in Her campaign to October 1,

USPTO grant strengthens Alterity’s IP position and opens a path for ATH434 into Parkinson’s disease investment. Patents rarely make headlines outside the biotech trade press, but for a clinical-stage company preparing to enter a pivotal trial, a strong patent estate can matter as much as the data itself. Alterity Therapeutics has just secured one of The post New patent strengthens Alterity’s Parkinson’s investment appeared first on Longevity.Technology.

THPharm already has a drug in late-stage trials. Now it’s using AI to work backwards and find out what else that drug might be good for. Drug development usually runs in one direction: pick a disease, search for a molecule that treats it, spend years finding out if you’re right. THPharm, a South Korean biotech The post AI hunts new uses for Phase 3 metabolic drug appeared first on Longevity.Technology.

The research community remains very interested in finding novel ways to promote muscle growth with minimal side effects. Therapies that inhibit myostatin or upregulate follistatin signaling are under development, and follistatin gene therapies have been available via medical tourism for some years. But most of the research community is focused on pharmacology, the use of small molecules to influence muscle metabolism. As an example of this type of work, researchers here report on a small molecule that mimics adiponectin signaling to promote muscle growth in rats. Skeletal muscle atrophy is a hallmark of ageing and chronic diseases, yet effective pharmacotherapies remain unavailable. Adiponectin signalling through receptors AdipoR1 and AdipoR2 regulates skeletal muscle metabolism, regeneration and oxidative capacity, but the therapeutic use of adiponectin is limited

Parkinson's disease and Lewy body dementia are synucleinopathies, characterized by the spread of misfolded α-synuclein through the central nervous system. The presence of misfolded α-synuclein provokes harmful changes in cell behavior and ultimately cell death in important populations of neurons. Researchers here explore differences in the vulnerability of different parts of the brain to the pathology produced by misfolded α-synuclein. They conclude that more complex parts of the brain, characterized by increased mitochondrial activity and greater connectivity between neurons, are more fragile in the face of the pathological mechanisms of syncleinopathy. A total of 89 patients with dementia with Lewy bodies and 89 matched controls underwent T1-weighted brain MRI. Scans were processed to generate surface-based cortical thickness maps. Regional cortical thickness estimates, after slice-by-slice manual

Exonate Limited has changed its name to Foventa Therapeutics and shifted its focus to clinical development for non-proliferative diabetic retinopathy. The new name is inspired by the fovea, and the company describes its motto as Simply Sharper. According to the company, Foventa is advancing FOV407, a topical retinal-penetrant small molecule SRPK1 inhibitor designed to act The post Exonate rebrands as Foventa Therapeutics to advance diabetic eye drop therapy appeared first on Longevity.Technology.

NorthStrive Biosciences has executed a First Amendment to its Development and License Agreement with Yuva Biosciences to launch a three-phase Expansion Program that will advance four AI-discovered small-molecule compounds toward lead nomination for potential cardiac disease and obesity therapeutics. The Expansion Program is structured to take approximately six months and builds on positive Phase III The post NorthStrive expands AI program with Yuva to nominate cardiac leads appeared first on Longevity.Technology.

Resolution Therapeutics has partnered with Blood Centers of America to support broad U.S. patient access to RTX001, its experimental Regenerative Macrophage Therapy for end-stage liver disease. The partnership will make BCA a preferred provider of cell collection and processing services for pivotal U.S. study sites and aims to enable treatment in community settings where most The post Resolution Therapeutics, BCA partner to expand access to experimental liver disease therapy appeared first on Longevity.Technology.

Oligomerix appointed Cara Cassino, M.D., as interim president and chief executive officer on 31 August 2026. According to the company, Cassino has 25 years of clinical drug development and commercialization experience across large pharmaceutical and biotech firms and more than 25 FDA and EMA drug approvals. Cassino has held senior roles at Boehringer Ingelheim and The post Oligomerix appoints new interim CEO to advance Alzheimer’s drug pipeline appeared first on Longevity.Technology.

As AI eats traffic, the best sites are locking it out, making reliable information harder to find. The post Content for Clicks: AI Is Tearing Up the Web’s Social Contract appeared first on SingularityHub.

Atherosclerosis is universal; everyone develops fatty atherosclerotic plaques in their arteries at some point, and to some degree. Plaques narrow blood vessels to impede blood flow, and rupture of unstable plaque causes heart attack, stroke, and embolism. It is the largest cause of human mortality, and at present the best that the medical community can do is to slow down plaque growth. Established therapies based on reducing the amount of cholesterol carried outward from the liver on low-density lipoprotein (LDL) particles produce something like a 15% mortality risk reduction at best, and do not regress plaque to any meaningful degree. Interestingly, the drivers of atherosclerosis are sufficiently complex and varied for there to be a few lucky people who exhibit 10% or more plaque regression

Properly untangling aging means untangling its various counterbalances, sometimes on the individual level. Here’s what’s been investigated this month. Interviews

Nature Medicine publication and late-breaking data put ImmunoBrain’s checkpoint immunotherapy and its clean safety profile in the spotlight. While much of Alzheimer’s drug development chases the disease’s hallmark proteins directly, ImmunoBrain Checkpoint is making its case from a different angle entirely: strengthening the body’s own immune system so it can help protect and repair the The post ImmunoBrain’s immune reset shows promise in Alzheimer’s appeared first on Longevity.Technology.

Longevity is becoming big business, but the science, standards and clinical practices needed to guide the field are still catching up. Longevity medicine is having a moment. Biological age tests, epigenetic clocks, peptide protocols, microbiome panels and increasingly elaborate health packages are no longer confined to the fringes of medicine. They are showing up in The post Who decides what counts as longevity medicine? appeared first on Longevity.Technology.

One-year trial results show most patients kept off GLP-1-induced weight loss after a single endoscopic procedure. GLP-1 drugs have transformed obesity treatment, but they have also created a new clinical problem: what happens when patients stop taking them. Weight regain after discontinuation is common and well documented, and it has opened a commercial opportunity for The post Fractyl Health’s Revita data show lasting weight loss appeared first on Longevity.Technology.

Biogen Inc. stock drew renewed attention after a Canadian advisory committee issued a final positive recommendation supporting public reimbursement of Leqembi, developed with partner Eisai, for Canadians with mild cognitive impairment or mild dementia due to early Alzheimer’s disease. The recommendation could lead to provincial and territorial funding decisions that expand access in Canada. According The post Canada recommends public funding for Alzheimer’s drug Leqembi appeared first on Longevity.Technology.

Oligomerix has appointed Dr. Cara Cassino as interim president and chief executive officer as the privately held biotech moves from discovery toward clinical development of its lead Alzheimer’s candidate. Cassino has served on the Oligomerix board since July 2025 and brings about 25 years of clinical drug development and commercialization experience that includes senior roles The post Oligomerix appoints new interim CEO to lead Alzheimer’s drug development appeared first on Longevity.Technology.

NeuroSense has redesigned its PrimeC development plan in amyotrophic lateral sclerosis to pursue a potential regulatory submission faster and at materially lower cost than its previously planned path. The program is structured as three focused elements: AI-enabled modeling of Phase 2b PARADIGM clinical data to characterize PrimeC’s formulation contribution, an active-comparator clinical study directly against The post NeuroSense speeds PrimeC path to potential approval in ALS appeared first on Longevity.Technology.

Celularity and MuseCell Innovations have agreed to establish U.S. manufacturing of Dezawa MuseCells at Celularity’s Florham Park, New Jersey, facility, with initial production to include DMCs and DMC-derived products such as Dezawa MuseExosomes and Dezawa MuseSecretome. The initial effort will focus on MCI-authenticated DMC preparations from qualified perinatal, bone marrow and adipose starting materials manufactured The post Celularity, MuseCell Innovations to build US Dezawa MuseCell plant appeared first on Longevity.Technology.

Oligodendrocytes resident in the brain are responsible for maintaining the insulating myelin sheaths around axons that are required for the effective transmission of electrical impulses between neurons. Loss of myelin integrity is the cause of a number of debilitating conditions, but also occurs to some degree with aging. It has been an open question as to how large a contribution this makes to age-related cognitive decline. Researchers here provide evidence for age-related changes in oligodendrocyte behavior and myelin structures to be more complicated than the simple concept of reduced remyelination and loss of myelin integrity, and to correlate with meaningful differences in the trajectory of cognitive decline in mice. The underlying mechanisms driving cognitive decline in aging remain unclear. Learning in humans in youth and

Delivered by injection, the drug transforms astrocytes into neurons. In an early study, mice modeling Alzheimer's showed marked improvement compared to untreated peers. The post This Drug Makes New Neurons in the Brain. Scientists Say It Reversed Alzheimer’s Symptoms in Mice. appeared first on SingularityHub.

Researchers have found that the sirtuin SIRT1 stabilizes the human genome by suppressing retrotransposition, which occurs when parts of the genome transcribe themselves onto other parts. When DNA modifies itself Long interspersed elements-1 (LINE-1)

NeuroQuant clearance automates amyloid quantification for Alzheimer’s imaging, trading radiologist’s judgment call for standardized number. Reading a brain scan for Alzheimer’s has long come down to a radiologist’s trained eye and best guess. That guesswork just got a software co-pilot with the FDA’s sign-off attached. Cortechs.ai announced on 18 August that its NeuroQuant PET platform The post FDA clears software that quantifies amyloid in Alzheimer’s appeared first on Longevity.Technology.

United Therapeutics will present four oral and four poster presentations at the European Society of Cardiology Congress 2026, 28-31 August in Munich, and at the European Respiratory Society Congress 2026, 5-9 September in Barcelona. Late-breaking analyses from the phase 3 ADVANCE OUTCOMES study indicate ralinepag achieved clinical improvement in a lower-risk pulmonary arterial hypertension population The post United Therapeutics presents positive Phase 3 lung disease study data appeared first on Longevity.Technology.

LifeVantage reported declines in revenue and earnings for the fourth quarter and full fiscal year 2026. For the quarter ended 30 June 2026, revenue was $42.4 million, down 23.1% year over year; net income per diluted share was $0.10 and adjusted earnings per diluted share were $0.11. Adjusted EBITDA for the quarter was $2.7 million. The post Lower order volume, GLP-1 system slump drive down LifeVantage fiscal 2026 sales appeared first on Longevity.Technology.

Mission Therapeutics and NeuraLight have partnered to deploy NeuraLight’s eye-movement-derived brain function biomarkers across Mission’s multinational MTX325 trial in Parkinson’s disease, spanning clinical sites in the UK, Europe and Australia. NeuraLight’s platform will provide objective, repeatable measures intended to quantify neural pathway function and detect subtle changes that conventional clinical scales may miss. MTX325 is The post Mission Therapeutics, NeuraLight partner on Parkinson’s biomarkers appeared first on Longevity.Technology.

Fresh NIH funding backs an iPSC-and-AI push to find drugs for Duchenne cardiomyopathy without relying on mouse models that rarely translate. By the numbers, the translational gap is expensive. Roughly nine in ten drug candidates that succeed in animal models still fail once they reach human trials, and cardiology has one of the worst records The post Greenstone bets on human cells to fix DMD hearts appeared first on Longevity.Technology.

Afterlife: freeze and upload  Eurozine

Every week, we scour the web for important, insightful, and fascinating stories in science and technology. The post This Week’s Awesome Tech Stories From Around the Web (Through August 29) appeared first on SingularityHub.

Recursive self-improvement, where AI continuously builds better versions of itself, might be harder than some hope. The post Are We on the Verge of an Intelligence Explosion? Maybe Not. appeared first on SingularityHub.

Michael Snyder, Director of the Center for Genomics and Personalized Medicine at Stanford University, is obsessed with health-tracking wearables. During our

AstronauTx has exercised its Saniona option, advancing a sleep-focused neurodegeneration candidate toward IND-enabling studies. Sleep has become one of the most talked-about levers in longevity science, credited with everything from metabolic health to cognitive resilience. AstronauTx, a UK biotech founded by SV Health’s Dementia Discovery Fund, is now translating that interest into a drug pipeline. The post AstronauTx turns sleep into new dementia target appeared first on Longevity.Technology.

Health-testing company pairs its member data with NYU Grossman’s clinical expertise to try to catch diseases before symptoms ever show up. Most of medicine still works the same way it did a century ago: something goes wrong, a person notices and only then does the system spring into action. Function Health thinks that order of The post Function, NYU take aim at disease before diagnosis appeared first on Longevity.Technology.

BTT Medical Institute, in collaboration with BTT Corp., has initiated a first-in-human clinical and biological safety trial (ClinicalTrials.gov Identifier: NCT07564440) to evaluate induced hyperthermia delivered by the Abreu BTT 700 Temperature Management System, a noninvasive computerized, brain-guided platform that raises body temperature into a controlled fever range through cyclical thermal modulation. The trial, approved by The post BTT begins first human safety trial using heat therapy for ALS appeared first on Longevity.Technology.

Celularity and MuseCell Innovations announced a U.S. manufacturing collaboration to establish production of Dezawa MuseCells at Celularity’s Florham Park, New Jersey facility. The initial program is intended to authenticate and manufacture Dezawa MuseCells from qualified perinatal, bone marrow or adipose sources using the licensed Dezawa Method and to include manufacturing of DMC-derived products such as The post Celularity to manufacture Dezawa MuseCells in U.S. appeared first on Longevity.Technology.

AlzeCure will present at the Pareto Securities 17th Annual Healthcare Conference in Stockholm on 2 September, with CEO Martin Jönsson scheduled to deliver a presentation and answer questions. The presentation and one-on-one meetings are planned at Hotel At Six, Brunkebergstorg 6, with the company scheduling the session for 17:05-17:25 CEST and saying the presentation will The post AlzeCure to showcase Alzheimer’s, pain research at Pareto Healthcare Conference appeared first on Longevity.Technology.

Can AI replace lawyers—at least in some circumstances? The post An ‘AI Legal Team’ Has Won Its First Case. It’s a Rare Victory for Access to Justice. appeared first on SingularityHub.

A recent study has examined whether senescence might allow cancer cells to survive oncogene withdrawal and become even more dangerous [1]. Some blocking techniques are temporary Many

Cryonic  moviefone.com

Seven months after ditching paper screening for Creyos, Claremedica is catching over 90% of new dementia cases at the earliest stage. Cognitive decline is often the one vital sign primary care does not routinely check. Claremedica, a value-based senior primary care organisation serving more than 34,000 Medicare Advantage patients across 35-plus sites in Florida, is The post Claremedica’s digital test finds 90% of new dementia cases early appeared first on Longevity.Technology.

Oligonucleotide drug slows Alzheimer’s decline across every dose tested in Phase 2 and reframes the field’s central therapeutic target. The Alzheimer’s Association International Conference has spent the last several years dominated by amyloid. This year, tau got its moment. Ionis Pharmaceuticals and partner Biogen presented full Phase 2 CELIA data for diranersen, an antisense oligonucleotide The post Ionis, Biogen deliver new tau data in Alzheimer’s appeared first on Longevity.Technology.

Oura Health is preparing for a potential U.S. initial public offering that could raise up to $3 billion and value the smart ring maker at more than $16 billion. The company filed confidentially for the IPO in May and has retained Goldman Sachs, Morgan Stanley, JPMorgan Chase, Allen & Co. and Jefferies as underwriters. The The post Smart ring maker Oura prepares for U.S. IPO at up to $3b raise appeared first on Longevity.Technology.

Retro Biosciences is expanding its phase 1 safety trial of RTR 242 by adding two higher-dose cohorts and increasing enrollment from 76 to 108 participants, a more than 42% rise. The trial is being conducted in Australia in healthy volunteers aged 18 to 65. The company claims RTR 242 is designed to restore lysosomal acidity The post Retro Biosciences expands early trial for drug targeting Alzheimer’s, Parkinson’s appeared first on Longevity.Technology.

Insilico Medicine released interim results for the first half of 2026, reporting total revenue of US$106.3 million, a year-over-year increase of 287.2%, and a gross profit margin of 90.3%. The company recorded a net profit of US$35.54 million, an adjusted net profit of US$51.23 million, positive operating cash flow, and held US$584.8 million in cash The post Insilico revenue surges 287% in H1 2026 driven by major pharma deals appeared first on Longevity.Technology.

Blade Runner Lost Script Reveals Tyrell Froze Himself: Real Cryonics Has Same Fatal Flaw  Tech Times

A new study compared high-intensity sprint-interval exercise with moderate-intensity exercise. The former produced larger changes in circulating protein and metabolite levels than the latter and

HEALTH survey suggests the longevity conversation is shifting from living longer toward living better and the industry may need to catch up. HEALTH’s new Longevity Insights Report, based on responses from 1,000 Americans, raises some uncomfortable questions for an industry racing toward the future: are biohackers building for an audience that doesn’t exist? While tech The post New survey reveals what Americans really want from longevity appeared first on Longevity.Technology.

Anavex reported a business update and financial results for the third fiscal quarter ended 30 June. The company has submitted all data from its Alzheimer’s disease clinical trials to a newly opened Alzheimer’s IND and intends to use EMA feedback and prior FDA interactions to inform a planned Phase 3 design. Anavex also reported that The post Anavex outlines progress in Alzheimer’s, rare disease studies with cash runway into 2028 appeared first on Longevity.Technology.

Alnylam will present new clinical and real-world data across its transthyretin-mediated amyloidosis and hypertension programs at ESC Congress 2026 in Munich on 28-31 August 2026. Presentations include late-breaking pre-specified analyses from the HELIOS-B Phase 3 study of AMVUTTRA (vutrisiran) assessing outcomes in patients on background stabilizer therapy, additional HELIOS-B analyses of healthy aging, functional capacity, The post Alnylam showcases late-breaking heart treatment, hypertension findings at ESC 2026 appeared first on Longevity.Technology.

Eisai and Biogen announced that LEQEMBI IQLIK (lecanemab-irmb) autoinjector is now available in the U.S. for initiation of therapy in adults with mild cognitive impairment or mild dementia due to Alzheimer’s disease, collectively referred to as early AD. For initiation, the approved regimen is 500 mg once weekly delivered as two consecutive 250 mg subcutaneous The post Eisai, Biogen launch at-home Leqembi autoinjector in the US for early Alzheimer’s appeared first on Longevity.Technology.

What if your healthcare could connect the dots between your bloodwork, sleep, genetics and everyday life – before something goes wrong? What if healthcare did not begin when you got sick? That question is the center of this week’s episode of Longevity.Technology UNLOCKED, in which ahead of this year’s Longevity Investors Conference, host Phil Newman The post Building a health system that puts prevention first appeared first on Longevity.Technology.

Self-contracting myografts improved muscle, bone and metabolic measures in aging mice – without requiring the animals to exercise. Researchers have engineered living muscle grafts that spontaneously contract beneath the skin and appear to reproduce some of exercise’s systemic effects, improving measures of muscle function, bone health and metabolism in aging mice [1]. The work, published The post Scientists create muscle that exercises itself appeared first on Longevity.Technology.

These lab-grown balls of brain tissue could help researchers study a host of disorders that emerge as the brain ages. The post Mini Brains Grown for Five Years Matured Like Human Brains appeared first on SingularityHub.

Icahn School of Medicine wins $1m award as its NYC-Vita trial pushes toward the finals of the world’s biggest healthy aging competition. Part of a ten-part series profiling each of the $101 million XPRIZE Healthspan competition’s Milestone 2 Awardees. Across the series, Longevity.Technology examines the science behind each team’s approach, the trial data supporting it The post Mount Sinai’s $1m XPRIZE bet: reset immune system, slow aging appeared first on Longevity.Technology.

Growth financing will help expand the Syn-One Test as investors place bigger bets on precision neurology and the future of earlier diagnosis. One of the biggest frustrations in neurology is that by the time diseases such as Parkinson’s become obvious, they have often been quietly progressing for years. The tremors, stiffness and movement problems people The post CND Life Sciences funding backs earlier Parkinson’s detection appeared first on Longevity.Technology.

AVLAYAH brought in $3.6 million in its first quarter, as Denali advanced its Alzheimer’s pipeline and banked $195m from a voucher sale. California-based Denali Therapeutics has posted its first quarterly revenue as a commercial-stage company, reporting $3.6 million in net product revenue from AVLAYAH (tividenofusp alfa-eknm) in the second quarter of 2026, its first full The post Denali Therapeutics’ brain-crossing drug hits market appeared first on Longevity.Technology.

AlzeCure collects its upfront payment from Eli Lilly for Alzheimer’s candidate ACD680, with a deal that could top $1 billion still in play. Ten million dollars landed in AlzeCure Pharma’s account this week. It’s not a huge number by pharma standards, but it’s the opening move in a deal that could eventually be worth more The post AlzeCure banks $10m as Lilly deal closes appeared first on Longevity.Technology.

NRG Therapeutics presented a poster at the ALS Association’s ALS Nexus conference (23–26 August 2026) detailing preclinical and mechanistic data for NRG5051, its orally bioavailable, CNS-penetrant inhibitor of the mitochondrial permeability transition pore. According to the company, NRG5051 acts through a novel NLRX1-mediated mechanism and showed profound anti-inflammatory and neuroprotective effects in acute NLS-TDP43 ALS The post NRG Therapeutics shows promising lab results for new ALS drug candidate appeared first on Longevity.Technology.

United Therapeutics announced that the U.S. Food and Drug Administration has accepted its New Drug Application for Ralinepag to treat pulmonary arterial hypertension and has set a Prescription Drug User Fee Act target action date of 24 June 2027, according to the company. The filing is based on results from the phase 3 ADVANCE OUTCOMES The post FDA accepts United Therapeutics’ application for hypertension drug appeared first on Longevity.Technology.

Eisai has begun U.S. availability of lecanemab-irmb subcutaneous injection, branded in the U.S. as Leqembi Iqlik, for initiation therapy in early Alzheimer’s disease after FDA approval on 13 July, according to the company. Leqembi Iqlik is the first-of-its-kind anti-amyloid treatment that offers at-home dosing for initiation and maintenance and is administered via an autoinjector as The post Eisai launches weekly injections for early Alzheimer’s in the US appeared first on Longevity.Technology.

The flashy company, which recently completed a blockbuster IPO, appears to be leading the pack of humanoid robot makers. The post Unitree Claims New Humanoid Robot Outruns Usain Bolt appeared first on SingularityHub.

Researchers have found that an upstream promoter of two extracellular matrix proteins increases healing and strength capabilities in the tendons of rats. Tendon injuries in older

Early human data suggest Vandria’s drug candidate VNA-318 may validate a new way of tackling age-related brain disease. In Alzheimer’s research, are scientists fighting the wrong battle? The field has spent decades trying to remove the sticky amyloid plaques that accumulate in the brain, yet the clinical benefits have often been modest and hotly debated. The post New Alzheimer’s contender Vandria clears key hurdle appeared first on Longevity.Technology.

A $29 add-on through Quest’s US labs turns routine bloodwork into a single number that tracks how fast or slow you’re aging. There’s a kind of frustration in getting a clean bill of health from a blood panel and still feeling like nobody actually answered the question you were asking: am I aging well? Humanity The post Quest, Humanity bring biological age test to 2,000 US locations appeared first on Longevity.Technology.

AliveCor announced a prospective cohort study (M-KEEPS) conducted by the University of Rochester and published in JACC Advances; according to the company, 30-day use of the handheld KardiaMobile 6L outperformed traditional short-duration ambulatory ECG monitoring in detecting clinically significant arrhythmias. The study evaluated 350 adults with unexplained palpitations, dizziness, or lightheadedness who used a physician-ordered The post KardiaMobile 6L outperforms traditional ECG monitors in new study appeared first on Longevity.Technology.

Rznomics is joining Lilly Gateway Labs in San Diego to accelerate discovery and development of RNA-based therapeutics. The Gateway Labs provide wet lab facilities and opportunities to engage with Lilly scientists and executives as part of Lilly Catalyze360, according to the company. The company plans to accelerate candidate discovery across a target gene database of The post Rznomics joins Lilly Gateway Labs in San Diego to advance RNA therapeutics appeared first on Longevity.Technology.

The U.S. Food and Drug Administration cleared C2N Diagnostics’ PrecivityAD2 blood test for use in adults as young as 40 who are experiencing signs of cognitive impairment. The Alzheimer’s Drug Discovery Foundation says it began funding C2N in 2008 and that its support, including a $7 million investment through the ADDF’s Diagnostics Accelerator, helped advance The post FDA approves PrecivityAD2 blood test for adults with cognitive decline appeared first on Longevity.Technology.

In a new study, mice recovered their memories by regrowing brain connections lost during artificial hibernation. The post We May Be Wrong About How the Brain Stores Memory appeared first on SingularityHub.

Collagevita’s Medical Director explains why regenerative treatments may need to start before the actual procedure does. Regenerative aesthetics increasingly works by persuading the skin to do more of the work itself – stimulating collagen production rather than simply replacing what time, hormones or weight loss have taken away. But there is a potential catch: sending The post Can we prime skin to regenerate better? appeared first on Longevity.Technology.

A new study suggests that in amyotrophic lateral sclerosis – and possibly other neurodegenerative diseases – the brain’s immune cells devour stressed but still living neurons due to altered signaling [1]. The living dead Amyotrophic lateral sclerosis

Pemvidutide’s balanced glucagon/GLP-1 action heads into pivotal MASH trial, testing if hitting two receptors evenly beats mono-agonist crowd. Altimmune has dosed its first patients in PERFORMA, the Phase 3 trial for pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) [1]. It’s a milestone moment for a drug that has spent years positioning itself as something other than The post Altimmune’s dual-hormone bet enters Phase 3 trial appeared first on Longevity.Technology.

EHE Health’s partnership with Prenuvo brings boutique preventive scanning and reopens an old debate about who gets access to early detection. For years, whole-body MRI screening has lived in a specific cultural lane: a Silicon Valley biohacker’s routine, a wellness-influencer talking point, a service marketed to people who already track their VO2 max and sleep The post Whole-body MRI is leaving the biohacker bubble appeared first on Longevity.Technology.

Niagen Bioscience announced that Tru Niagen is now available at nearly 300 GNC and Sam’s Club retail locations across 44 states and online at both retailers, according to the company. At GNC, the assortment includes Tru Niagen Beauty, which the company describes as the first U.S. beauty supplement featuring Niagen (patented nicotinamide riboside), and Tru The post Top-selling NAD+ supplement Tru Niagen lands at GNC, Sam’s Club appeared first on Longevity.Technology.

Fractyl Health will host a virtual Commercial Strategy Day on 1 September 2026 at 11:00 AM ET to outline the potential commercial opportunity and go-to-market strategy for Revita. The event follows what the company describes as positive one-year randomized data from the REMAIN-1 Midpoint Cohort showing weight maintenance one year after a single Revita procedure; The post Fractyl Health to host virtual commercial strategy day appeared first on Longevity.Technology.

Mitochon Pharmaceuticals has been awarded a $1 million Hoffman ALS Clinical Trial Award from the ALS Association to support a 24-week sporadic amyotrophic lateral sclerosis study. The funding is intended to expand on recent clinical work in Europe that the company claims showed a rapid reduction in neurofilament light levels among sporadic ALS participants taking The post Mitochon receives $1m award for ALS phase 2 study appeared first on Longevity.Technology.

Using cohort studies and a mouse model, researchers have found that the circulating factor ANGPTL8, which is produced by senescent fat cells, is related to age-related diseases and mortality in mice and people. Too much of a regulator leads

Phase 2a study completes enrollment as biotech tests whether treating joint inflammation could slow osteoarthritis, not just ease pain. Mention GLP-1 today and most people immediately think of weight loss. Drugs like Ozempic and Wegovy have transformed the conversation around obesity and diabetes, becoming some of the biggest medical success stories of the decade. But The post 4Moving Biotech targets inflammation in knee osteoarthritis trial appeared first on Longevity.Technology.

Corundum Corp’s Maayan Eilon-Ashkenazy explains why human biological age is far too complex to be measured by just one simple clock. The longevity field has been preoccupied with quantifying biological age, often distilling it to just one, highly marketable number. But aging does not move through the body as a single clock. It leaves different The post The longevity trap appeared first on Longevity.Technology.

FDA accelerates development of XellSmart’s off-the-shelf Parkinson’s therapy, raising questions about the direction of regenerative medicine. Recently, Chinese regenerative medicine company XellSmart reached an important milestone after the US Food and Drug Administration (FDA) granted Fast Track Designation to XS411, its investigational cell therapy for Parkinson’s disease [1]. The designation is reserved for therapies that The post XellSmart scores FDA fast track for Parkinson’s cell therapy appeared first on Longevity.Technology.

Drug mimics a hormone you make when you push hard at the gym – early results suggest it could help to keep weight off after stopping GLP-1s. There’s a hormone your body releases when you go hard on a run or push through a tough set at the gym. It’s called Lac-Phe, and scientists only The post Enveda makes ‘exercise pill’ that skips the treadmill appeared first on Longevity.Technology.